MD Anderson Cancer Center’s Post

My philosophy, as a physician, is to do whatever I can to preserve both quality and length of life. #Focalblatepro; #Urodocs; #FocaltherapyProstate

My philosophy, as a physician, is to do whatever I can to preserve both quality and length of life. #Focalblatepro; #Urodocs; #FocaltherapyProstate

We spoke with Farrukh Awan, MD, University of Texas Southwestern Medical Center, about some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years. "At some point, we hope to have a strategy that would cure or permanently eliminate the disease in a small subset of our patients. However, it's hard to quantify cures in CLL because the remission period is so long that we have to follow patients for a long period of time to definitively say that the cancer has completely been eliminated and will not come back after stopping therapy," said Dr Awan. Watch the full interview here: https://lnkd.in/dy4v4HJz #JournalOfClinicalPathways #CLL #ChronicLymphocyticLeukemia #CancerCare

We sat down with Farrukh Awan, MD, University of Texas Southwestern Medical Center, about some of the most promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL). "There are ongoing comparative trials, which are trying determine whether combination time-limited therapy of the two most active compounds—BTK inhibitors and the BPL2 inhibitors—will result in a better outcome for our patients in the long run. I highly recommend all our patients to participate in those trials," said Dr Awan. Check out the full interview here: https://lnkd.in/dG6dua2p #JournalOfClinicalPathways #CLL #ChronicLymphocyticLeukemia #ClinicalTrials #ValueBasedCare

Increased risk of #colorectalcancer as second primary cancer in #patients w/ #breastcancer & #BRCA1 positive #germline #genetictesting https://lnkd.in/gmY9G7Wf #JCO c/w 0.4% prevalence of #BRCA1 PGVs in cohort of 30K #patients w/ #CRC https://lnkd.in/gbsW8Ntp #JCOPrecisionOncology American Society of Clinical Oncology (ASCO) University of Pennsylvania Perelman School of Medicine Invitae Crucial to identify #genetic #risk in #patients w/ #cancer to increase screening for downstaging and/or prevent #second #cancer diagnosis. Too many #patients w/ #cancer suffer a #second #preventable #cancer 2/2 lack of #germlinetesting https://lnkd.in/g6S8gxx JAMA Network Open #access #reducedisparities #universal #germlinetesting #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention

The importance of evidence in the 2024 breast cancer screening guideline https://lnkd.in/gea2aqgX

Promising Allogeneic TCR Therapy for Pediatric Relapsed Acute Myeloid Leukemia Researchers at Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands presents a promising approach to enhance outcomes for pediatric acute myeloid leukemia (AML) patients post-transplant. They engineered allogeneic cord blood-derived CD8+ T cells with a specific T-cell receptor (TCR) targeting the tumour-associated antigen WT1, achieving high efficiency and potent cytotoxicity against AML cells. Endogenous TCR was also removed from those cells to prevent them from attacking host healthy cells. These edited T cells showed enhanced function and migration without harming healthy cells. This strategy offers a potential off-the-shelf therapy to prevent relapse, significantly improving the clinical outlook for children with AML after hematopoietic cell transplantation. The link to the original article is in the comments. If you found this post valuable, give it a like and share it with your network! 😃 #PediatricAML #TCRTherapy #LeukemiaResearch #HematopoieticTransplant #CordBloodTCells #CellTherapy #ImmunoOncology #CancerResearch Be at the forefront of cancer immunotherapy breakthroughs! 🔬 Subscribe for FREE to my weekly Newsletter for a dose of knowledge and the latest advancements: https://lnkd.in/ec5sV-iP 📧 #ImmunotherapyFrontiers #StayInformed #ImmunotherapyExploration #DontMissOut"

Exploring Pediatric NLPHL: Insights from a Low-Middle-Income Country This comprehensive study delves into pediatric nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), offering valuable insights into its complexity, treatment challenges, and outcomes. It examines the effectiveness of different chemotherapy regimens and highlights the importance of tailored treatment approaches, particularly in resource-limited settings. Understanding the evolving nature of NLPHL treatments is crucial for improving patient outcomes globally. This study emphasizes the potential of R-CHOP over ABVD, showing better progression-free survival rates. The findings highlight that early-stage NLPHL patients have excellent survival rates, but challenges remain for advanced-stage treatment. What innovative strategies do you believe could further enhance treatment for NLPHL globally? Full Article Available here: https://lnkd.in/e3hfT_Yj #PediatricOncology #HodgkinLymphoma #OncologyResearch #CancerTreatment #GlobalHealth

#ASCO24 Update Very poignant question: 🙋 18 months Versus 36 Months of Androgen deprivation therapy In patients with high risks of Prostate cancer who are receiving radiotherapy. Testosterone recovery improves the quality of life ie sexual function in males with prostate cancer. This study presented at #ASCO24 suggests that 18 months is appropriate American Society of Clinical Oncology (ASCO)